Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival (OS) in untreated fit patients; humanized ant...

Descripción completa

Detalles Bibliográficos
Autor principal: Smolej, Lukáš
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325625/
https://www.ncbi.nlm.nih.gov/pubmed/25691812
http://dx.doi.org/10.2147/PGPM.S55501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4325625/
https://www.ncbi.nlm.nih.gov/pubmed/25691812
http://dx.doi.org/10.2147/PGPM.S55501

Ejemplares similares